US Patent Issued to Ultragenyx Pharmaceutical on Feb. 10 for "Methods for improved therapeutic use of recombinant AAV" (California Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,437, issued on Feb. 10, was assigned to Ultragenyx Pharmaceutical Inc. (Novato, Calif.).

"Methods for improved therapeutic use of recombinant AAV" was invented by Barbara Anne Sullivan (Tiburon, Calif.) and Kathleen Phillips Mckeever (San Anselmo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated vims (rAAV) to a subject following administration of a CD 19 inhibitor, e.g., an anti-CD 19 antibody. The methods described herein can ...